Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis

X
Trial Profile

GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GTB 3550 (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Mast Cell Leukemia; Myelodysplastic syndromes; Systemic mastocytosis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors GT Biopharma
  • Most Recent Events

    • 21 Mar 2022 Status changed from active, no longer recruiting to discontinued.
    • 15 Sep 2021 Status changed from recruiting to active, no longer recruiting.
    • 15 Sep 2021 According to a GT Biopharma media release, data from the study will be presented at the European Society for Medical Oncology (ESMO) Congress 2021. The abstract is currently available on the ESMO website at www.esmo.org. At the start of the mini-oral session the presentation will be available in the "Presentations" section of the Company's website at https://www.gtbiopharma.com.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top